
World's First! Affiliated Eye Hospital of Wenzhou Medical University Successfully Conducts Targeted BCMA Universal CAR-T Cell Therapy for NMOSD
Wu Wencan's team completed the world's first universal CAR-T cell therapy for relapsed/refractory NMOSD. The patient showed improved vision and discontinued steroids, confirming the therapy's safety and feasibility while providing a new option for similar optic nerve immune diseases.
The Affiliated Eye Hospital of Wenzhou Medical University